首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1746874

日本生物樣本庫市場報告（按樣本類型、生物樣本庫類型、應用、最終用戶和地區）2025-2033

Japan Biobanking Market Report by Specimen Type, Biobank Type, Application, End User, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 119 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本生物樣本庫市場規模達38.03億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到56.11億美元，2025-2033年期間的複合年成長率（CAGR）為4.4%。個人化醫療需求的不斷成長，以及對生物樣本和資料（用於支持研究和客製化治療開發）的需求不斷成長，共同推動著市場的發展。

生物樣本庫是現代醫療保健和科學研究的一個重要面向。它涉及系統地收集、儲存和管理個體生物樣本，例如血液、組織和DNA，以備將來用於研究、診斷和治療開發。生物樣本庫在增進我們對疾病、遺傳學和個人化醫療的理解方面發揮著至關重要的作用。這些儲存庫在嚴格的倫理和監管準則下保存樣本及其相關資料，確保患者的隱私和知情同意。生物樣本庫樣本是研究疾病、識別生物標記和測試新療法的寶貴資源。它們有助於進行大規模縱向研究，揭示健康和疾病隨時間推移的模式和趨勢。生物樣本庫促進了研究人員之間的合作，加速了醫學發現，並增強了根據個體基因組成製定個人化治療方案的可能性。它還支持轉化研究，彌合實驗室發現與臨床應用之間的差距。總而言之，生物樣本庫是現代醫療保健的關鍵基礎設施，有助於推進醫學知識並改善病患照護。

日本生物銀行市場趨勢：

日本生物樣本庫市場正經歷強勁成長，這得益於幾個關鍵促進因素。首先，醫學研究的進步和對個人化醫療的日益關注推動了對生物樣本庫服務的需求。這些生物樣本庫使研究人員能夠獲得各種各樣的樣本，從而加速他們了解疾病和開發標靶療法的努力。此外，人們越來越意識到保存生物材料以供未來研究的重要性，這促使公共和私營部門增加對生物樣本庫基礎設施的投資。此外，癌症和心血管疾病等慢性疾病的盛行率不斷上升，需要建立廣泛的生物樣本庫來支持生物標記和治療標靶的發現。基因組醫學的普及以及遺傳資訊與醫療保健實踐的整合進一步擴大了對生物樣本庫解決方案的需求。最後，監管措施和倫理考量強化了圍繞生物樣本庫的框架，增強了利害關係人的信心並鼓勵他們參與。這些相互關聯的促進因素正推動日本生物樣本庫市場實現前所未有的成長，並預示著未來醫療成果的改善和醫學領域的突破。

日本生物銀行市場細分：

樣本類型洞察：

血液製品
實體組織
細胞系
核酸
其他

生物樣本庫類型洞察：

基於人群的生物樣本庫
以疾病為導向的生物樣本庫

應用程式洞察：

療法
研究

最終用戶洞察：

學術機構
製藥和生物技術公司

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本生物銀行市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物銀行市場有何影響？
根據樣本類型，日本生物銀行市場是如何分類的？
根據生物樣本庫類型，日本生物樣本庫市場是如何分類的？
日本生物銀行市場根據應用如何分類？
根據最終用戶，日本生物銀行市場是如何分類的？
日本生物銀行市場的價值鏈分為哪些階段？
日本生物銀行的主要促進因素和挑戰是什麼？
日本生物銀行市場的結構是怎麼樣的？主要參與者有哪些？
日本生物銀行市場的競爭程度如何？

本報告回答的關鍵問題：

日本生物銀行市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物銀行市場有何影響？
根據樣本類型，日本生物銀行市場是如何分類的？
根據生物樣本庫類型，日本生物樣本庫市場是如何分類的？
日本生物銀行市場根據應用如何分類？
根據最終用戶，日本生物銀行市場是如何分類的？
日本生物銀行市場的價值鏈分為哪些階段？
日本生物銀行的主要促進因素和挑戰是什麼？
日本生物銀行市場的結構是怎麼樣的？主要參與者有哪些？
日本生物銀行市場的競爭程度如何？

Japan biobanking market size reached USD 3,803 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 5,611 Million by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033. The increasing demand for personalized medicine, coupled with the growing need for biological samples and data to support research and the development of tailored treatments, is driving the market.

Biobanking is a crucial aspect of modern healthcare and scientific research. It involves the systematic collection, storage, and management of biological samples, such as blood, tissue, and DNA, from individuals for future use in research, diagnostics, and treatment development. Biobanks play a vital role in advancing our understanding of diseases, genetics, and personalized medicine. These repositories preserve specimens and their associated data under strict ethical and regulatory guidelines, ensuring patient privacy and informed consent. Biobanked samples serve as valuable resources for studying diseases, identifying biomarkers, and testing new therapies. They facilitate large-scale, longitudinal studies that can uncover patterns and trends in health and disease over time. Biobanking promotes collaboration among researchers, accelerates medical discoveries, and enhances the potential for tailored treatments based on an individual's genetic makeup. It also supports translational research, bridging the gap between laboratory findings and clinical applications. In summary, biobanking is a critical infrastructure in modern healthcare, advancing medical knowledge and improving patient care.

Japan Biobanking Market Trends:

The biobanking market in Japan is experiencing robust growth due to several key drivers. Firstly, advancements in medical research and the increasing focus on personalized medicine have propelled the demand for biobanking services. These repositories of biological samples enable researchers to access a diverse range of specimens, accelerating their efforts in understanding diseases and developing targeted therapies. Moreover, the growing awareness of the importance of preserving biological materials for future research has prompted both public and private sector investments in biobanking infrastructure. In addition to this, the rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, necessitates extensive biobanking to support the discovery of biomarkers and therapeutic targets. The adoption of genomic medicine and the integration of genetic information into healthcare practices have further amplified the demand for biobanking solutions. Lastly, regulatory initiatives and ethical considerations have strengthened the framework surrounding biobanking, instilling confidence among stakeholders and encouraging their participation. These interconnected drivers are propelling the biobanking market in Japan towards unprecedented growth, promising a future of improved healthcare outcomes and medical breakthroughs.

Japan Biobanking Market Segmentation:

Specimen Type Insights:

Blood Products
Solid Tissue
Cell Lines
Nucleic Acid
Others

Biobank Type Insights:

Population-based Biobanks
Disease-oriented Biobanks

Application Insights:

Therapeutics
Research

End User Insights:

Academic Institutions
Pharma and Biotech Companies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan biobanking market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biobanking market?
What is the breakup of the Japan biobanking market on the basis of specimen type?
What is the breakup of the Japan biobanking market on the basis of biobank type?
What is the breakup of the Japan biobanking market on the basis of application?
What is the breakup of the Japan biobanking market on the basis of end user?
What are the various stages in the value chain of the Japan biobanking market?
What are the key driving factors and challenges in the Japan biobanking?
What is the structure of the Japan biobanking market and who are the key players?
What is the degree of competition in the Japan biobanking market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biobanking Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biobanking Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Biobanking Market - Breakup by Specimen Type

6.1 Blood Products
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Solid Tissue
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Cell Lines
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Nucleic Acid
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2019-2024)
- 6.5.2 Market Forecast (2025-2033)

7 Japan Biobanking Market - Breakup by Biobank Type

7.1 Population-based Biobanks
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Disease-oriented Biobanks
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Biobanking Market - Breakup by Application

8.1 Therapeutics
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Research
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)

9 Japan Biobanking Market - Breakup by End User

9.1 Academic Institutions
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Pharma and Biotech Companies
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)

10 Japan Biobanking Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Biobanking Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis